FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body
Drugs.com
MAY 27, 2025
TUESDAY, May 27, 2025 -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.Through.
Let's personalize your content